{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=15", "query": { "intervention": "TMZ", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 469, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T15:48:20.667Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00715793", "title": "Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hussein Tawbi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715793" }, { "nct_id": "NCT03705351", "title": "Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Cancer of Brain", "Glioblastoma Multiforme", "Brain Tumor" ], "interventions": [ { "name": "Tumor Treating Fields", "type": "DEVICE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DEVICE", "DRUG", "RADIATION" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 7, "start_date": "2019-12-02", "completion_date": "2022-02-24", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 2, "location_summary": "San Francisco, California • Portland, Oregon", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03705351" }, { "nct_id": "NCT00597402", "title": "Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Brain Tumor" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy (XRT)", "type": "RADIATION" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2007-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-05-07", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597402" }, { "nct_id": "NCT00525031", "title": "Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide (TMZ)", "type": "DRUG" }, { "name": "Pegylated Interferon Alpha-2b (PGI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2006-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2020-09-23", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525031" }, { "nct_id": "NCT00884741", "title": "Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Supratentorial Glioblastoma" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 637, "start_date": "2009-04-15", "completion_date": "2013-03-17", "has_results": true, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 324, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884741" }, { "nct_id": "NCT00734864", "title": "Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Glioma" ], "interventions": [ { "name": "enzyme-inducing anti-epileptic drugs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annick Desjardins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-06", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-11-21", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734864" }, { "nct_id": "NCT00662506", "title": "Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Perfusion Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2008-04", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662506" }, { "nct_id": "NCT01505608", "title": "Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "TPI 287", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 14, "start_date": "2011-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 8, "location_summary": "Phoenix, Arizona • San Diego, California • Hartford, Connecticut + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505608" }, { "nct_id": "NCT06721689", "title": "PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Solid Tumors", "Relapsed Solid Tumors", "Relapsed Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Rhabdomyosarcoma", "Refractory Rhabdomyosarcoma" ], "interventions": [ { "name": "PEEL-224", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theodore Laetsch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 59, "start_date": "2025-03-23", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06721689" }, { "nct_id": "NCT00629343", "title": "Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma", "Mesothelioma" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2007-10", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-10-19T15:48:20.667Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00629343" } ] }